专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006102375A2 METHODS FOR AVOIDING EDEMA IN THE TREATMENT OR PREVENTION OF PPARγ-RESPONSIVE DISEASES, INCLUDING CANCER 审中-公开
标题翻译：在治疗或预防PPAR治疗方面避免艾滋病的方法 - 包括癌症
公开(公告)号：WO2006102375A2
公开(公告)日：2006-09-28
申请号：PCT/US2006/010331
申请日：2006-03-21
申请人： METABOLEX, INC. , SANDERS, Martin, E. , KARPF, David, B.
发明人： SANDERS, Martin, E. , KARPF, David, B.
IPC分类号： A61K31/428
CPC分类号： A61K31/428 , A61K31/5377 , A61K2300/00
摘要： Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided.
摘要翻译：提供了使用衍生物和前药在治疗或预防PPARα介导的疾病（包括癌症）中避免水肿的化合物，组合物和方法。

2. 发明申请

WO2007035857A3 TREATMENT OF B CELL DISEASES USING ANTI-GERMLINE ANTIBODY BINDING AGENTS 审中-公开
公开(公告)号：WO2007035857A3
公开(公告)日：2007-03-29
申请号：PCT/US2006/036784
申请日：2006-09-19
申请人： PALINGEN, INC. , SANDERS, Martin, E.
发明人： SANDERS, Martin, E.
IPC分类号： A61K39/395 , C07K16/42 , G01N33/53
摘要： Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune disease are provided, comprising contacting the blood or plasma of the patient with an immunoadsorbent having specific binding for an epitope present on germline antibodies, particularly VH4-34 antibodies, wherein said contacting results in the reduction in the amount of germline antibodies present in the blood or bone marrow or lymphoid tissue of the patient or the amount of germline antibody producing B cells present in the blood, lymphoid tissues or bone marrow of the patient. Methods for treating a patient suffering from a B cell cancer expressing cell surface germline antibodies by similar methods are also provided. Methods for ex vivo purging bone marrow of pathologic antibody producing B-cells and cancerous B- cells expressing germline antibodies are provided. Methods for monitoring the efficacy of a therapeutic treatment in a patient suffering from an autoimmune disease or B cell cancer are also provided. Kits and uses in preparation of a medicament are also described.

3. 发明申请

WO2007092427A2 TREATMENT OF ENDOTOXEMIA USING ENDOTOXIN NEUTRALIZING AGENTS 审中-公开
标题翻译：使用内毒素中和剂治疗内毒素
公开(公告)号：WO2007092427A2
公开(公告)日：2007-08-16
申请号：PCT/US2007/003121
申请日：2007-02-06
申请人： PALINGEN, INC. , SANDERS, Martin, E.
发明人： SANDERS, Martin, E.
CPC分类号： C07K16/1203 , C07K16/44 , G01N33/579 , G01N33/6893 , G01N2800/26 , G01N2800/52
摘要： Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood; and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the patient has elevated endotoxin levels. The methods can further comprise treating patients identified as having elevated levels of endotoxin with an endotoxin neutralizing therapy. The methods provide increased safety and a reduction in risk for critically ill patients.
摘要翻译：公开了用于选择患有内毒素血症以治疗内毒素中和剂的患者的方法和组合物，其包括：（a）测定患者血液中的内毒素水平; 和（b）将患者血液中的内毒素水平与预定的阈值内毒素水平进行比较，以确定患者是否具有升高的内毒素水平。所述方法可以进一步包括用内毒素中和治疗治疗被鉴定为具有升高的内毒素水平的患者。这些方法提供了危重病人的安全性和风险降低。

4. 发明申请

WO2006052641A3 ANTIBODY INDUCED CELL MEMBRANE WOUNDING 审中-公开
公开(公告)号：WO2006052641A3
公开(公告)日：2006-05-18
申请号：PCT/US2005/039762
申请日：2005-11-04
申请人： PALINGEN, INC. , BHAT, Neelima, M. , BIEBER, Marcia, M. , TENG, Nelson, N., H. , SANDERS, Martin, E.
发明人： BHAT, Neelima, M. , BIEBER, Marcia, M. , TENG, Nelson, N., H. , SANDERS, Martin, E.
IPC分类号： C07K16/00 , A61K38/00 , C07K1/00
摘要： Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo , the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients’ refractory to the chemotherapeutic agents.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式